SCHEMBL3602519

SCHEMBL3602519

Nc1ccc2c(c1)NC(=O)C(N1CC[C@H](O)C1)C2

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CRBN Q96SW2 6/20 0.40
CA9 Q16790 1/20 0.40
TRPV1 Q8NER1 3/20 0.36
DRD2 P14416 1/20 0.36
DRD4 P21917 1/20 0.36
KMT2A Q03164 3/20 0.36
MEN1 O00255 2/20 0.36
APEX1 P27695 1/20 0.36
TDP1 Q9NUW8 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
DDB1 Q16531 3/20 0.35
KDM4E B2RXH2 3/20 0.34
MAPT P10636 3/20 0.34
GAA P10253 2/20 0.34
IKZF3 Q9UKT9 2/20 0.33
ALDH1A1 P00352 2/20 0.33
ROCK2 O75116 1/20 0.32
ALOX15 P16050 1/20 0.32
HSD17B10 Q99714 1/20 0.32
SMN1; SMN2 Q16637 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3600127 0.93 CA9 (0.41) CRBNCA9TRPV1DRD2DRD4
SCHEMBL3600507 0.90 CRBN (0.40) CRBNCA9TRPV1DRD2DRD4
SCHEMBL13545482 0.86 CRBN (0.41) CRBNCA9TRPV1DRD2DRD4
SCHEMBL3596750 0.86 CRBN (0.41) CRBNCA9TRPV1DRD2DRD4
SCHEMBL3602518 0.85 TRPV1 (0.36) CRBNTRPV1DRD2DRD4KMT2A
SCHEMBL3604336 0.82 DRD2 (0.42) CRBNTRPV1DRD2DRD4KMT2A
SCHEMBL13545286 0.82 TRPV1 (0.42) TRPV1DRD2DRD4KMT2AMEN1
SCHEMBL13545486 0.82 CRBN (0.38) CRBNCA9TRPV1DRD2DRD4
SCHEMBL3597005 0.82 CA9 (0.45) CRBNCA9TRPV1DRD2DRD4
SCHEMBL3600796 0.81 TSHR (0.46) CRBNCA9TRPV1DRD2DRD4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100016285-A1 HETEROCYCLIDENE-N-(ARYL) ACETAMIDE DERIVATIVE MOCHIDA PHARMACEUTICAL CO., LTD. (JP) 2010-01-21 US disclosed
EP-2128157-A1 HETEROCYCLIDENE-N-(ARYL)ACETAMIDE DERIVATIVE MOCHIDA PHARMACEUTICAL CO., LTD. (JP) 2009-12-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100016285-A1 HETEROCYCLIDENE-N-(ARYL) ACETAMIDE DERIVATIVE CCNY, CCND3, NSD3 CRBN 762/4885CA9 1531/4885TRPV1 2518/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.